Arvinas, Inc (ARVN)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 246
- Market Cap
- $553M
About Arvinas, Inc
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
SentiSense also tracks daily options readings for Arvinas, Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Arvinas, Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.